Pozycja agomelatyny w leczeniu depresji

• Authors: Łukasz Święcicki , Bogdan Stefanowski

Title variants

EN

Agomelatine in the management of depression

• Languages of publication: PL

Abstracts

PL

Na rynku dostępnych jest wiele leków przeciwdepresyjnych, ale wykorzystują one jedynie kilka wspólnych mechanizmów działania. Ponieważ znaczny odsetek pacjentów nie reaguje wystarczająco dobrze na stosowane leki, pojawienie się leku o nowym mechanizmie działania, takiego jak agomelatyna, zawsze budzi nadzieje. W artykule przedstawiono wyniki metaanaliz i badań kontrolowanych, a także kilku badań otwartych dotyczących pewnych szczególnych aspektów terapii. Zaprezentowane badania zostały opublikowane w ostatnich latach – w roku 2013 i później. Wyniki metaanaliz nie są jednoznaczne, ale nowsze publikacje mogą wskazywać na wysoką skuteczność agomelatyny. Co istotne, nie potwierdzają się wcześniejsze opinie o znacznej hepatotoksyczności leku. Rezultaty badań kontrolowanych niemal jednoznacznie wskazują, że pod względem skuteczności i bezpieczeństwa agomelatyna nie ustępuje lekom przeciwdepresyjnym z grupy selektywnych inhibitorów wychwytu zwrotnego serotoniny. Przeprowadzone w ostatnich latach badania dotyczące wpływu agomelatyny na anhedonię mają charakter badań otwartych, agomelatyna nie była w nich porównywana z innymi lekami przeciwdepresyjnymi, stąd też trudno jednoznacznie zinterpretować uzyskane wyniki.

EN

Various antidepressants are available on the market, most of them relying on a few common mechanisms of action. Since response to treatment in a large percentage of patients is not satisfying, the emergence of drugs with a novel mechanism of action, as is the case with agomelatine, invariably offers new hope. The article offers a review of the results of meta-analyses and placebo-controlled studies as well as several open-label trials concerning given aspects of therapy. The reviewed studies have all been published over the recent years, starting in 2013. The meta-analyses have yielded equivocal results, yet the newer studies seem to point to the high efficiency of agomelatine. Importantly, the validity of earlier concerns regarding the significant hepatotoxicity of agomelatine has not been confirmed. The results of placebo-controlled trials have fairly unanimously demonstrated the effectiveness and safety of agomelatine to be in no way inferior to that of selective serotonin reuptake inhibitors. The recent studies investigating the effect of agomelatine on anhedonia have all been open-label trials, with agomelatine not compared with other antidepressants, hence it is difficult to interpret the outcomes unequivocally.

Keywords

EN

agomelatyna; duża depresja; lek przeciwdepresyjny

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2018
• Volume: 18
• Issue: 1
• Pages: 81–86

Contributors

author

Łukasz Święcicki

• II Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii, Warszawa, Polska

author

Bogdan Stefanowski

• II Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii, Warszawa, Polska

References

• Corruble E, de Bodinat C, Belaïdi C et al.; agomelatine study group: Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol 2013; 16: 2219–2234.
• Demyttenaere K, Corruble E, Hale A et al.: A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr 2013; 18: 163–170.
• Gahr M: Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Curr Neuropharmacol 2014; 12: 387–398.
• Gargoloff PD, Corral R, Herbst L et al.: Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Hum Psychopharmacol 2016; 31: 412–418.
• Gorwood P, Demyttenare K, Vaiva G et al.: An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness. J Affect Disord 2015a; 185: 97–103.
• Gorwood P, Vaiva G, Corruble E et al.: The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatr Dis Treat 2015b; 11: 2875–2882.
• Guaiana G, Gupta S, Chiodo D et al.: Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013; (12). CD008851.
• Kasper S, Hajak G: The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol 2013; 23: 814–821.
• Kennedy SH, Eisfeld BS: Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr Dis Treat 2007; 3: 423–428.
• Kennedy SH, Avedisova A, Belaïdi C et al.: Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol 2016; 26: 378–389.
• Kennedy SH, Avedisova A, Giménez-Montesinos N et al.; Agomelatine Study Group: A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder. Eur Neuropsychopharmacol 2014; 24: 553–563.
• Khoo AL, Zhou HJ, Teng M et al.: Network meta-analysis and costeffectiveness analysis of new generation antidepressants. CNS Drugs 2015; 29: 695–712.
• Koesters M, Guaiana G, Cipriani A et al.: Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013; 203: 179–187.
• Komaram RB, Nukala S, Palla J et al.: A comparative study of efficacy and safety of agomelatine and escitalopram in major depressive disorder. J Clin Diagn Res 2015; 9: VC05–VC08.
• Korzeniowski L, Pużyński S (eds.): Encyklopedyczny słownik psychiatrii. 3rd ed., PZWL, Warszawa 1986.
• Laux G, Barthel B, Hajak G et al.: Pooled analysis of four non-interventional studies: effectiveness and tolerability of the antidepressant agomelatine in daily practice. Adv Ther 2017; 34: 895–914.
• Montgomery SA, Nielsen RZ, Poulsen LH et al.: A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014; 29: 470–482.
• Plesničar BK: Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence 2014; 8: 603–612.
• Shu L, Sulaiman AH, Huang YS et al.: Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50 mg or fluoxetine 20–40 mg in Asian out-patients with major depressive disorder. Asian J Psychiatr 2014; 8: 26–32.
• Udristoiu T, Dehelean P, Nuss P et al.: Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25–50 mg/day) and escitalopram (10–20 mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised doubleblind comparative study. J Affect Disord 2016; 199: 6–12.
• Vinckier F, Gourion D, Mouchabac S: Anhedonia predicts poor psychosocial functioning: results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry 2017; 44: 1–8.

• Document Type: article